1. Bim suppresses the development of SLE by limiting myeloid inflammatory responses
- Author
-
Tsai, FuNien, Homan, Philip J., Agrawal, Hemant, Misharin, Alexander V., Abdala-Valencia, Hiam, Haines, G. Kenneth, Dominguez, Salina, Bloomfield, Christina L., Saber, Rana, Chang, Anthony, Mohan, Chandra, Hutcheson, Jack, Davidson, Anne, Budinger, G.R. Scott, Bouillet, Philippe, Dorfleutner, Andrea, Stehlik, Christian, Winter, Deborah R., Cuda, Carla M., and Perlman, Harris
- Abstract
The Bcl-2 family is considered the guardian of the mitochondrial apoptotic pathway. We demonstrate that Bim acts as a molecular rheostat by controlling macrophage function not only in lymphoid organs but also in end organs, thereby preventing the break in tolerance. Mice lacking Bim in myeloid cells (LysMCreBimfl/fl) develop a systemic lupus erythematosus (SLE)–like disease that mirrors aged Bim−/− mice, including loss of marginal zone macrophages, splenomegaly, lymphadenopathy, autoantibodies (including anti-DNA IgG), and a type I interferon signature. LysMCreBimfl/fl mice exhibit increased mortality attributed to glomerulonephritis (GN). Moreover, the toll-like receptor signaling adaptor protein TRIF (TIR-domain–containing adapter-inducing interferon-β) is essential for GN, but not systemic autoimmunity in LysMCreBimfl/fl mice. Bim-deleted kidney macrophages exhibit a novel transcriptional lupus signature that is conserved within the gene expression profiles from whole kidney biopsies of patients with SLE. Collectively, these data suggest that the Bim may be a novel therapeutic target in the treatment of SLE.
- Published
- 2017
- Full Text
- View/download PDF